Cellectar Biosciences, Inc. Resources
Patients
News & Media
Investors
Contact
Cellectar Biosciences, Inc.
Home
About
Overview
Partnerships
Management Team
Board of Directors
Platform
Overview
Posters & Publications
Product Pipeline
Overview
Iopofosine
Clinical Studies
Overview
Waldenstrom’s Macroglobulinemia Phase 2 Study
Active, not recruiting
Relapsed or Refractory Select B-Cell Malignancies Clinical Study
Active, not recruiting
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Active, not recruiting
Patients
News & Media
Investors
Contact
Proxy Information
Cellectar Biosciences' Annual Meeting will be held on June 13, 2019 in the Executive Conference Center on the 1st Floor at 100 Campus Drive, Florham Park, NJ 07932 and it will begin at 10:00am ET.
Meeting Location:
Definitive Proxy Statement
Proxy Card
10-K for 2019
